EV Biologics, Inc. (YECO)
USD 0.14
(0.0%)
USD 0.14
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.26 Million USD | 18.13% |
| 2022 | -21.05 Million USD | -2332.15% |
| 2021 | -387.69 Thousand USD | 75.49% |
| 2020 | -98.96 Thousand USD | -0.57% |
| 2019 | -98.4 Thousand USD | 0.0% |
| 2017 | -6.63 Million USD | -86.57% |
| 2016 | -5.81 Million USD | -62.35% |
| 2015 | -46.56 Million USD | -11.92% |
| 2014 | 14.62 Million USD | 9.49% |
| 2013 | 16.53 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 85.42 Thousand USD | 144.6% |
| 2024 Q2 | -191.55 Thousand USD | 3.11% |
| 2024 Q1 | -11.2 Thousand USD | 65.05% |
| 2023 FY | - USD | 18.13% |
| 2023 Q2 | -84.46 Thousand USD | -8.77% |
| 2023 Q4 | -375.8 Thousand USD | -74.06% |
| 2023 Q3 | -215.9 Thousand USD | -155.62% |
| 2023 Q1 | -77.65 Thousand USD | 85.17% |
| 2022 Q3 | -8960.00 USD | 74.01% |
| 2022 FY | - USD | -2332.15% |
| 2022 Q2 | -34.48 Thousand USD | 0.0% |
| 2022 Q4 | -523.49 Thousand USD | -5742.62% |
| 2021 Q2 | - USD | 100.0% |
| 2021 FY | - USD | 75.49% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q1 | -157.3 Thousand USD | 0.0% |
| 2020 FY | - USD | -0.57% |
| 2019 FY | - USD | 0.0% |
| 2017 FY | - USD | -86.57% |
| 2017 Q4 | 49.38 Million USD | 0.0% |
| 2017 Q2 | -273.21 Thousand USD | 0.0% |
| 2017 Q1 | -273.21 Thousand USD | 84.65% |
| 2016 FY | - USD | -62.35% |
| 2016 Q4 | -1.78 Million USD | -94.84% |
| 2016 Q3 | -913.62 Thousand USD | 88.23% |
| 2016 Q2 | -7.76 Million USD | -286.37% |
| 2016 Q1 | 4.16 Million USD | 5.3% |
| 2015 Q1 | 3.49 Million USD | 1.9% |
| 2015 Q4 | 3.95 Million USD | -22.93% |
| 2015 Q3 | 5.13 Million USD | 24.29% |
| 2015 FY | - USD | -11.92% |
| 2015 Q2 | 4.12 Million USD | 18.28% |
| 2014 Q4 | 3.42 Million USD | -7.92% |
| 2014 Q1 | 3.95 Million USD | 3.3% |
| 2014 Q2 | 4.77 Million USD | 20.88% |
| 2014 Q3 | 3.72 Million USD | -22.1% |
| 2014 FY | - USD | 9.49% |
| 2013 Q2 | 3.6 Million USD | 5.14% |
| 2013 Q1 | 3.42 Million USD | -15.84% |
| 2013 Q3 | 4.05 Million USD | 12.55% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | 3.82 Million USD | -5.68% |
| 2012 Q4 | 4.07 Million USD | 99899.98% |
| 2012 Q3 | 4071.43 USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 98.216% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 78.628% |
| SQZ Biotechnologies Company | -64.14 Million USD | 98.024% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 92.705% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.347% |
| Mesoblast Limited | -62.38 Million USD | 97.969% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 17.507% |
| Genus plc | 73.7 Million USD | 101.719% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 80.834% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 64.276% |
| Marizyme, Inc. | -34.28 Million USD | 96.304% |
| ContraFect Corporation | -64.99 Million USD | 98.051% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 85.555% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 72.004% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 9.607% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 52.083% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 45.472% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -144.598% |
| Accustem Sciences Inc. | -3.74 Million USD | 66.178% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 97.373% |
| Q BioMed Inc. | -617.62 Thousand USD | -105.161% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 135.474% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -100.367% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 44.533% |
| Biomind Labs Inc. | -1.03 Million USD | -22.482% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 112.829% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 82.306% |
| Skye Bioscience, Inc. | -13.54 Million USD | 90.647% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 14.81% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -4968.528% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 67.378% |
| IMV Inc. | -35.52 Million USD | 96.433% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 92.015% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 49.354% |
| GB Sciences, Inc. | -1.41 Million USD | 10.758% |
| Alpha Cognition Inc. | -9.7 Million USD | 86.944% |
| HST Global, Inc. | -5303.00 USD | -23794.626% |
| CSL Limited | 4.78 Billion USD | 100.026% |
| Halberd Corporation | -74.27 Thousand USD | -1605.909% |
| Enzolytics Inc. | -2.12 Million USD | 40.287% |
| Resverlogix Corp. | -11.74 Million USD | 89.209% |
| Affymax, Inc. | -14.29 Million USD | 91.136% |
| SYBLEU INC | -141.57 Thousand USD | -795.051% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 58.631% |
| argenx SE | -216.02 Million USD | 99.413% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 97.71% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 204.119% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 15.463% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 434.473% |
| AVAX Technologies, Inc. | -6.11 Million USD | 79.27% |
| Zenith Capital Corp. | -8.6 Million USD | 85.276% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.491% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -7173.589% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 48.206% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -619.862% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 96.803% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 56.19% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -21.105% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 18944.914% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 27.592% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 34.035% |
| BioStem Technologies, Inc. | -7.55 Million USD | 83.225% |
| ONE Bio Corp. | 13.61 Million USD | 109.308% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -599.733% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 38.399% |
| Agentix Corp. | -1.37 Million USD | 7.627% |
| LadRx Corporation | 412.28 Thousand USD | 407.345% |
| Cell Source, Inc. | -4.27 Million USD | 70.342% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -245.06% |
| Regen BioPharma, Inc. | 1.46 Million USD | 186.437% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -35.24% |
| NovAccess Global Inc. | -1.03 Million USD | -22.452% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 114.312% |
| Itoco Inc. | -1.86 Million USD | 32.202% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -233.79% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -13.542% |
| Kadimastem Ltd | -2.62 Million USD | 51.717% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -429.848% |
| CytoDyn Inc. | -18.02 Million USD | 92.972% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -1503.376% |
| Mobile Lads Corp. | -2.24 Million USD | 43.461% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -10261.698% |
| Qrons Inc. | -40.08 Thousand USD | -3061.428% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -160.9% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 340.245% |
| Rebus Holdings, Inc. | -951 Thousand USD | -33.242% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -19.315% |
| International Stem Cell Corporation | 202 Thousand USD | 727.293% |
| Bioxytran, Inc. | -3.82 Million USD | 66.83% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2307.166% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 48.531% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 96.467% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -2715.849% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 53.721% |
| Neutra Corp. | -181.24 Thousand USD | -599.119% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 93.714% |
| PureTech Health plc | -11.62 Million USD | 89.102% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 93.714% |
| IXICO plc | -707 Thousand USD | -79.227% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 83.512% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 97.379% |
| CSL Limited | 4.73 Billion USD | 100.027% |
| Cellectis S.A. | -92.63 Million USD | 98.632% |